杂合子家族性高胆固醇血症患儿的治疗 - Suppr | 超能文献

Treatment of children with heterozygous familial hypercholesterolemia.

作者信息

Reiner Željko, Sahebkar Amirhossein

机构信息

University Hospital Center Zagreb, Department of Internal Medicine, Kišpatićeva 12, University of Zagreb, Croatia.

Halal Research Center of IRI, FDA, Tehran, Iran; Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran; Neurogenic Inflammation Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.

出版信息

Int J Cardiol. 2020 Apr 1;304:177-178. doi: 10.1016/j.ijcard.2019.10.055. Epub 2019 Nov 6.

DOI:10.1016/j.ijcard.2019.10.055

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Treatment of children with heterozygous familial hypercholesterolemia.杂合子家族性高胆固醇血症患儿的治疗

Int J Cardiol. 2020 Apr 1;304:177-178. doi: 10.1016/j.ijcard.2019.10.055. Epub 2019 Nov 6.

2

Heterozygous Familial Hypercholesterolemia.杂合子家族性高胆固醇血症

Circulation. 2016 Apr 5;133(14):e587-9. doi: 10.1161/CIRCULATIONAHA.115.020701.

3

Statin intolerance in heterozygous familial hypercolesterolemia with cardiovascular disease: After PCSK-9 antibodies what else?载脂蛋白 B 单克隆抗体在杂合子家族性高胆固醇血症合并心血管疾病中的应用：PCSK-9 抗体之后还有什么？

Eur J Prev Cardiol. 2017 Sep;24(14):1528-1531. doi: 10.1177/2047487317712419. Epub 2017 May 30.

4

Familial hypercholesterolemia: current treatment and advances in management.家族性高胆固醇血症：当前的治疗方法及管理进展

Expert Rev Cardiovasc Ther. 2008 Apr;6(4):567-81. doi: 10.1586/14779072.6.4.567.

5

Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial.载脂蛋白 B 代谢物单克隆抗体 AMG 145 降低杂合子家族性高胆固醇血症患者低密度脂蛋白胆固醇的作用：载脂蛋白 B 代谢物单克隆抗体 AMG 145 降低杂合子家族性高胆固醇血症患者低密度脂蛋白胆固醇的随机试验（RUTHERFORD）

Circulation. 2012 Nov 13;126(20):2408-17. doi: 10.1161/CIRCULATIONAHA.112.144055. Epub 2012 Nov 5.

6

Treatment of Heterozygous Familial Hypercholesterolemia in Children and Adolescents: An Unsolved Problem.儿童和青少年杂合子家族性高胆固醇血症的治疗：一个未解决的问题。

Rev Esp Cardiol (Engl Ed). 2017 Jun;70(6):423-424. doi: 10.1016/j.rec.2017.02.008. Epub 2017 Mar 9.

7

Subclinical coronary atherosclerosis and cardiovascular risk stratification in heterozygous familial hypercholesterolemia patients undergoing statin treatment.杂合子家族性高胆固醇血症患者他汀类药物治疗后的亚临床冠状动脉粥样硬化与心血管风险分层。

Curr Opin Lipidol. 2019 Apr;30(2):82-87. doi: 10.1097/MOL.0000000000000573.

8

Additive effects of another kind of HMG-CoA reductase inhibitor with different pharmacokinetics in the treatment of heterozygous familial hypercholesterolemia.另一种具有不同药代动力学的HMG-CoA还原酶抑制剂在治疗杂合子家族性高胆固醇血症中的相加作用。

Atherosclerosis. 2000 Dec;153(2):525-6. doi: 10.1016/s0021-9150(00)00626-2.

9

Association of specific LDL receptor gene mutations with differential plasma lipoprotein response to simvastatin in young French Canadians with heterozygous familial hypercholesterolemia.在患有杂合子家族性高胆固醇血症的年轻法裔加拿大人中，特定低密度脂蛋白受体基因突变与血浆脂蛋白对辛伐他汀的不同反应之间的关联。

Arterioscler Thromb Vasc Biol. 1998 Jun;18(6):1007-12. doi: 10.1161/01.atv.18.6.1007.

10

Genetic determinants of responsiveness to the HMG-CoA reductase inhibitor fluvastatin in patients with molecularly defined heterozygous familial hypercholesterolemia.分子定义的杂合子家族性高胆固醇血症患者对HMG-CoA还原酶抑制剂氟伐他汀反应性的遗传决定因素。

Circulation. 1993 Apr;87(4 Suppl):III35-44.

引用本文的文献

1

Dyslipidemia management for primary prevention of cardiovascular events: Best in-clinic practices.用于心血管事件一级预防的血脂异常管理：最佳临床实践

Prev Med Rep. 2022 May 5;27:101819. doi: 10.1016/j.pmedr.2022.101819. eCollection 2022 Jun.

2

Risk Assessment and Clinical Management of Children and Adolescents with Heterozygous Familial Hypercholesterolaemia. A Position Paper of the Associations of Preventive Pediatrics of Serbia, Mighty Medic and International Lipid Expert Panel.杂合子家族性高胆固醇血症儿童和青少年的风险评估与临床管理。塞尔维亚预防儿科学会、Mighty Medic及国际脂质专家小组的立场文件。

J Clin Med. 2021 Oct 25;10(21):4930. doi: 10.3390/jcm10214930.